White House to distribute monkeypox vaccines — Analysis

The White House is set to hand out nearly 2 million monkeypox vaccines in the coming months, beginning with an initial phase of around 300,000 doses as part of a new national strategy against the potentially dangerous virus.

The Joe Biden Administration announced Tuesday the strategy, noting that 56,000 vaccination doses would go to each of them “immediately,”Then, 240,000 more shots were added “over the coming weeks.”Additional 1.6 Million doses will also be offered in the second half of this year.

“The vaccine strategy will help immediately address the spread of the virus by providing vaccines across the country to individuals at high risk,” the White House said, adding that the first leg of the plan “aims to rapidly deploy vaccines in the most affected communities and mitigate the spread of the disease.”

Further, the administration stated that vaccines were being requested by 32 jurisdictions. More than 9,000 doses of antiviral treatment and more than 9000 have been distributed. The Centers for Disease Control and Prevention (CDC), which confirmed 305 cases of monkeypox in the US as of Tuesday afternoon, said that more than 4,400 had been identified abroad.

US buys millions of vaccine doses for dangerous virus

White House stated that they would also distribute vaccines to hundreds of thousands. “dramatically expand”After the CDC started shipping tested kits to major commercial labs, monkeypox testing began all over the country. The CDC published the protocol to the tests in order to improve access. This protocol can also be used without FDA approval by third-party laboratories. 

In May, health agencies agreed to purchase up to 13,000,000 doses of Jynneos vaccine from Danish pharmaceutical company Bavarian Nordic. This multi-million-dollar deal was made for monkeypox vaccines. Although the vaccine was initially developed for smallpox in 1999, it was later approved by FDA for monkeypox use in 2019. Although the White House won’t have access to new contracts until 2019, it will be able to use existing stock. 

ACAM2000 is another vaccination that will be offered to the states and territories in order to augment the Jynneos supply. ACAM2000 is also approved for smallpox. The White House has warned that it can be used for both purposes. “carries greater risk of certain serious side effects”For those who have existing immune and heart conditions

Monkeypox is rare but has been reported in the US. One Texas resident was hospitalized last summer due to the virus after she traveled to West Africa. According to the World Health Organization, there were more than 70 confirmed cases in America in 2003. This was the first case outside Africa.

The symptoms of the infection include headaches and muscle pains as well as fever and swollen lymph nodes. Although most cases resolve quickly, it can be deadly in some instances.

Officials from top health comment on monkeypox spreading

Share this story via social media



Related Articles

Back to top button